Improving the HIV PrEP Cascade Using an Intervention for Healthcare Providers
PrEP-OI
1 other identifier
interventional
10
1 country
1
Brief Summary
The PrEP Optimization Intervention (PrEP-OI) aims to educate healthcare providers on PrEP and assist providers in the appropriate targeting of patients at increased risk for HIV acquisition, initiating PrEP when appropriate, and providing guidance on the ongoing monitoring and adherence counseling of patients on PrEP. The intervention includes a web-based panel management tool (called PrEP-Rx) and PrEP coordination (by a PrEP Coordinator). The PrEP-OI study will take place among participating primary care and specialty clinics across the San Francisco Department of Public Health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2018
CompletedFirst Posted
Study publicly available on registry
May 22, 2018
CompletedStudy Start
First participant enrolled
November 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2021
CompletedSeptember 17, 2025
September 1, 2025
1.9 years
April 29, 2018
September 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy of PrEP-OI
Mean number of PrEP prescriptions initiated
10 months
Secondary Outcomes (3)
PrEP usage
10 months
Sustainability during 12 month Follow-up Phase
22 months
Facilitators and barriers of PrEP delivery
22 months
Study Arms (2)
PrEP-OI Intervention
EXPERIMENTALAll clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
Control until randomized for intervention
NO INTERVENTIONAll clinics that have not yet initiated the intervention at this time (i.e., control clinics). A new clinic will cross over to receive the intervention each month, with the order of clinic crossover determined at random, until all clinics are receiving the intervention.
Interventions
Eligibility Criteria
You may qualify if:
- San Francisco Department of Public Health (DPH) clinics that have agreed to participate
- HCPs and medical directors employed at the study clinics
- Patients who are seen at these study clinics and are offered HIV PrEP during the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCSF Center for AIDS Prevention Studies
San Francisco, California, 94158, United States
Related Publications (7)
Saberi P, Stoner MCD, Ming K, Lisha NE, Hojilla JC, Scott HM, Liu AY, Steward WT, Johnson MO, Neilands TB. The effect of an HIV preexposure prophylaxis panel management strategy to increase preexposure prophylaxis prescriptions. AIDS. 2022 Nov 1;36(13):1783-1789. doi: 10.1097/QAD.0000000000003283. Epub 2022 Jun 22.
PMID: 35730363RESULTShrestha I, Ming K, Jimenez V, Wendelborn J, Vazquez A, Steward W, Scott H, Saberi P. Lessons Learned from an HIV Pre-Exposure Prophylaxis Coordination Program in San Francisco Primary Care Clinics. AIDS Res Hum Retroviruses. 2022 Aug;38(8):611-614. doi: 10.1089/AID.2022.0013. Epub 2022 Jun 16.
PMID: 35592996RESULTSaberi P, Ming K, Shrestha I, Scott H, Thorson B, Liu A. Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics. Open Forum Infect Dis. 2022 Jan 21;9(2):ofab657. doi: 10.1093/ofid/ofab657. eCollection 2022 Feb.
PMID: 35087913RESULTChan CT, Ming K, Camp C, Saberi P. Sexual Behaviors, Substance Use, and Quality of Life Among Individuals Using PrEP in San Francisco During the COVID-19 Pandemic Shelter-In-Place Orders: A Cross-Sectional Survey. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):e39-e42. doi: 10.1097/QAI.0000000000002900. No abstract available.
PMID: 34974469RESULTSaberi P, Ming K, Scott H, Liu A, Steward W. "You can't have a PrEP program without a PrEP Coordinator": Implementation of a PrEP panel management intervention. PLoS One. 2020 Oct 16;15(10):e0240745. doi: 10.1371/journal.pone.0240745. eCollection 2020.
PMID: 33064763RESULTMing K, Shrestha I, Vazquez A, Wendelborn J, Jimenez V, Lisha N, Neilands TB, Scott H, Liu A, Steward W, Johnson MO, Saberi P. Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol. BMJ Open. 2020 Jul 14;10(7):e040734. doi: 10.1136/bmjopen-2020-040734.
PMID: 32665393RESULTSaberi P, Ming K, Hojilla JC, Scott HM, Neilands TB. HIV Preexposure Prophylaxis in the Time of COVID-19: How a Robust and Responsive HIV Preexposure Prophylaxis Intervention Can Avert Loss of HIV Prevention Coverage During a Global Pandemic. J Acquir Immune Defic Syndr. 2021 May 1;87(1):e173-e176. doi: 10.1097/QAI.0000000000002652. No abstract available.
PMID: 33534275RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Parya Saberi, PharmD, MAS
University of California, San Francisco
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 29, 2018
First Posted
May 22, 2018
Study Start
November 1, 2018
Primary Completion
September 30, 2020
Study Completion
January 31, 2021
Last Updated
September 17, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share